Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd3514. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 5/20 | 1.00 |
| ▸ | BRD4 | O60885 | 6/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075208 | 0.97 | AR (0.94) | ARBRD4KCNH2DRD3MCHR1 | |
| SCHEMBL3067867 | 0.96 | AR (0.92) | ARBRD4KCNH2DRD3MCHR1 | |
| Azd3514 SCHEMBL3061666 | 0.96 | AR (0.91) | ARBRD4KCNH2DRD3MCHR1 | |
| Azd3514 SCHEMBL3056460 | 0.96 | AR (0.91) | ARBRD4KCNH2DRD3MCHR1 | |
| Azd3514 SCHEMBL3056456 | 0.96 | AR (0.91) | ARBRD4KCNH2DRD3MCHR1 | |
| SCHEMBL3078457 | 0.92 | AR (0.84) | ARBRD4KCNH2 | |
| SCHEMBL3076370 | 0.90 | AR (0.81) | ARBRD4KCNH2DRD3MCHR1 | |
| SCHEMBL24592117 | 0.89 | AR (0.81) | ARBRD4KCNH2DRD3HRH3 | |
| SCHEMBL3075518 | 0.89 | AR (0.80) | ARBRD4KCNH2DRD3MCHR1 | |
| SCHEMBL3074474 | 0.89 | AR (0.80) | ARBRD4KCNH2DRD3MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070133-A | Pharmaceutical compositions containing androgen receptor inhibitors/antagonists, methods and uses | 苏州开拓药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20250345334-A1 | METHODS OF TREATING PROSTATE CANCER | UNIV CHICAGO (US) | 2025-11-13 | — | — | US | claimed |
| WO-2025111339-A1 | TREATMENT OF CANCER WITH A PARG INHIBITOR | 858 THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250127908-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | claimed |
| WO-2025081091-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025051237-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANDROGEN RECEPTOR INHIBITOR/ANTAGONIST, METHOD AND USE | 苏州开拓药业股份有限公司 | 2025-03-13 | — | — | WO | claimed |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-02-04 | — | — | US | claimed |
| US-12202815-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-21 | — | — | US | claimed |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | claimed |
| WO-2024010815-A2 | NON-STEROIDAL DUAL ANDROGEN AND GLUCOCORTICOID RECEPTOR ANTAGONISTS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-01-11 | — | — | WO | claimed |
| WO-2022104097-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-03-15 | — | — | US | claimed |
| EP-3946629-A1 | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS | University Of Massachusetts (US) | 2022-02-09 | — | — | EP | claimed |
| WO-2015042170-A1 | COMPOSITIONS AND USES OF COMBINATIONS OF DIM-RELATED INDOLES AND SELECTED ANTI-ANDROGEN COMPOUNDS | WAYNE STATE UNIVERSITY (US) | 2015-03-26 | — | — | WO | claimed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | claimed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | claimed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | claimed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | claimed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | claimed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127908-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | BRDT, NFKBIA, SSB | AR 4330/4885BRD4 27/4885KCNH2 4786/4885 |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | AR 1/4885BRD4 622/4885KCNH2 2070/4885 |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | AR 1/4885BRD4 57/4885KCNH2 3286/4885 |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | AR 1/4885BRD4 394/4885KCNH2 3633/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | AR 1/4885BRD4 628/4885KCNH2 1878/4885 |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | AR 1/4885BRD4 57/4885KCNH2 3286/4885 |
| US-12202815-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, FSHR | AR 1/4885BRD4 832/4885KCNH2 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.